Pharming (PHAR) Income towards Parent Company (2019 - 2025)
Historic Income towards Parent Company for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $22.3 million.
- Pharming's Income towards Parent Company rose 9508.5% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 12011.89%. This contributed to the annual value of -$233.0 million for FY2024, which is 463.71% down from last year.
- As of Q3 2025, Pharming's Income towards Parent Company stood at $22.3 million, which was up 9508.5% from -$10.0 million recorded in Q2 2025.
- Over the past 5 years, Pharming's Income towards Parent Company peaked at $22.3 million during Q3 2025, and registered a low of -$227.2 million during Q4 2024.
- Over the past 5 years, Pharming's median Income towards Parent Company value was -$174.9 million (recorded in 2021), while the average stood at -$106.7 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 25133.09% in 2021, then crashed by 10873166.02% in 2022.
- Over the past 5 years, Pharming's Income towards Parent Company (Quarter) stood at $15.0 million in 2021, then tumbled by 1427.92% to -$199.1 million in 2022, then dropped by 13.32% to -$225.6 million in 2023, then decreased by 0.68% to -$227.2 million in 2024, then soared by 109.8% to $22.3 million in 2025.
- Its Income towards Parent Company was $22.3 million in Q3 2025, compared to -$10.0 million in Q2 2025 and -$14.7 million in Q1 2025.